Research programme: small molecule therapeutics - Vanqua Bio
Latest Information Update: 24 Sep 2021
At a glance
- Originator Vanqua Bio
- Class Antidementias; Antiparkinsonians; Small molecules
- Mechanism of Action Complement system protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease; Huntington's disease; Parkinson's disease
Most Recent Events
- 14 Sep 2021 Early research in Alzheimer's disease in USA (unspecified route) (Vanqua Bio Pipeline, September 2021)
- 14 Sep 2021 Early research in Huntington's disease in USA (unspecified route) (Vanqua Bio Pipeline, September 2021)
- 14 Sep 2021 Early research in Parkinson's disease in USA (unspecified route) (Vanqua Bio Pipeline, September 2021)